Comptroller

Job Description

Altesa BioSciences is searching for a Comptroller/Director of Finance to join the team.

This is a remote job opportunity for a candidate in the metro-Atlanta or DC area.

Duties and Responsibilities shall include:

Serve as a financial advisor to the CEO and executive team for strategic planning purposes

Develop an appropriate system of policies and maintain internal controls appropriate for GAAP.

Oversee all sides of accounting operations, including payables, receivables, payroll, and tax preparation

Develop appropriate tracking methods for revenue and expenses.

Oversee development, oversight, and management of the organization’s investment plan

Lead and manage the budgeting process

Gather financial data for analysis and forecasting with respect to profits, trends, costs, and compliance

Coordinate the preparation of annual, quarterly, and monthly reports

Manage insurance coverage for the organization, including compliance, lead the company’s activities with external auditors and manage internal controls.

Qualifications

Education and Qualifications:

BA/BS Degree, CPA or equivalent

5-10+ years’ experience in a finance function

Prior Biotech/pharma experience

Thorough knowledge of GAAP, SEC, SOX

Additional Information

Altesa Biosciences provides equal employment opportunities to all employees and applicants for employment and prohibits discrimination and harassment of any type without regard to race, color, religion, age, sex, national origin, disability status, genetics, protected veteran status, sexual orientation, gender identity or expression, or any other characteristic protected by federal, state or local law

Company Description

Altesa Biosciences, Inc is a biopharmaceutical company based in Atlanta, GA focused on developing and commercializing novel anti-viral drugs against common respiratory viruses and global viral threats. Altesa has a formal partnership with Drug Innovation Ventures at Emory (DRIVE), a wholly-owned, not-for-profit drug discovery entity within Emory University. That collaboration includes a license to ALT-2023, a broadly active nucleoside analogue that is late-stage preclinical development, as well as options to additional compounds addressing RNA viruses. Altesa has also in-licensed Vapendavir, a Phase 2 antiviral broadly active against enteroviruses, including rhinovirus, that is currently in development for COPD patients.

Altesa Biosciences is led by its CEO, Brett P. Giroir, MD, former Assistant Secretary for Health and Acting FDA Commissioner; and a highly successful and experienced management team advised by world leaders in science and clinical medicine.

The Altesa Scientific Advisory Board (SAB) is comprised of academic and industry leaders in pulmonology, infectious diseases, virology, pediatrics and drug development, and s chaired by George Painter, Ph.D., Professor, Department of Pharmacology and Chemical Biology at the Emory University School of Medicine, and President and CEO of both DRIVE and the Emory Institute for Drug Development.